1. Home
  2. Medical Research
  3. Newport Beach, CA
  4. Cystinosis Research Foundation

Cystinosis Research Foundation

Cystinosis Research Foundation is ranked among medical research organizations in Newport Beach, CA, with an America's Best Score of 75 out of 100, based on its 2025 Form 990.

  • Newport Beach, CA
  • Tax-exempt since 2003
  • EIN: 32-0067668
cystinosisresearch.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
75OF 100 Ranked in Newport Beach Medical Research How this score is calculated

Organization summary

Cystinosis Research Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H80). Contributions are tax-deductible.

3501 Amboree Rd Ste 6100 N Tower, Newport Beach, CA 92660-0000

Among the 4 scored medical research organizations in Newport Beach, Cystinosis Research Foundation holds 26.3 months of operating reserves (peer median 1.7 months), runs a typical yearly surplus of 2.7% (peers: deficit of 13.5%), and has grown spending 3.8% a year (peers: cut spending 4.5% a year).

In fiscal year 2025 it reported $3,177,424 in revenue and $3,438,007 in expenses, with contributions making up 77.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

CRF is committed to finding a cure through an aggressively funded research agenda. CRF awards research grants bi-annually to accelerate the research process and to ensure that there is never a gap in funding new, cutting-edge research projects. CRF is dedicated to improving the quality of life for cystinosis patients and to finding better treatments, including a cure, for our adults and children living with cystinosis.

Main program · fiscal year 2025

  • EDUCATIONThe Cystinosis Research Foundation is dedicated to educating the cystinosis community, the public and the medical community about cystinosis to ensure early diagnosis and immediate and proper treatment.NATALIES WISHNatalies wish, To have my disease go away forever, was the driving force and inspiration that led to the establishment of the Cystinosis Research Foundation (CRF) in 2003. We k… Read more

    EDUCATIONThe Cystinosis Research Foundation is dedicated to educating the cystinosis community, the public and the medical community about cystinosis to ensure early diagnosis and immediate and proper treatment.NATALIES WISHNatalies wish, To have my disease go away forever, was the driving force and inspiration that led to the establishment of the Cystinosis Research Foundation (CRF) in 2003. We knew at that moment that we needed to make every effort to make Natalies wish and the wish of others with cystinosis a reality.HISTORY AND RESEARCHCystinosis is a rare, metabolic, genetic disease that afflicts approximately 2,500 children and adults worldwide. CRF is increasingly focused on funding clinical and translational research which is crucial to finding new treatments and a cure for cystinosis. CRF is committed to prioritizing and aggressively supporting research that has the potential to significantly improve the quality of life for children and adults with cystinosis. RESEARCH GIVES US HOPEWe firmly believe that funding and supporting research gives our community hope for a brighter future for those living with cystinosis. Hope allows us to live with cystinosis until the day a cure is found. Since 2003, the Cystinosis Research Foundation (CRF) has raised over $73 million and has become the worlds leading fund provider of cystinosis research. CRF has strategically and aggressively invested millions of dollars into the CRF research program creating a thriving and collaborative global research community that has changed the course of cystinosis. From the beginning, all CRF operating costs have been privately underwritten, so 100 percent of all donations received by CRF go to support cystinosis research. CRF HAS CREATED A CONTINUOUS CYCLE OF RESEARCH STUDIES BY SEEKING NEW RESEARCH APPLICATIONS TWICE A YEAR. We are pleased to announce that during the 12-month period ending June 30, 2025, CRF announced seven new grantS, AND GRANT PAYMENTS totaling $2,326,589,TO bring us that much closer to better treatments and a cure. RESEARCH PROGRESSFROM THE START OF THE FOUNDATION, WE HAVE UNDERSTOOD THAT FUNDING BASIC AND BENCH RESEARCH WAS important to understanding the cystinosis. Over the years, as discoveries were made in the lab, CRF began funding clinical research, and now we are translating the DATA FROM the clinical studies To the patients. Our strategy of providing seed money to talented researchers has been successful. Our first project involved funding researchers who were focused on a new treatment. CRF provided grants that funded every bench and clinical trial that led to the discovery of a delayed-release form of the life-saving medication for cystinosis. That medication, Procysbi was approved by the FDA on April 30, 2013, and is considered the most significant advancement in the treatment of cystinosis in 30 years. In 2007, CRF began funding Dr. Stphanie Cherqui, at UC San Diego who was focused on stem cell and gene therapy research. As a direct result of CRFs early and continuous funding, in December 2018, the FDA approved a clinical trial to assess the efficacy and safety of a stem cell and gene therapy treatment for cystinosis patients. In October 2019, the first cystinosis patient received the stem cell gene therapy treatment. In 2020, two patients received the therapy. In November 2021, the fourth patient received the treatment and in March 2022, the fifth patient received the treatment. The sixth and final patient in Phase I/II of the clinical trial was treated in October 2022. THE GRANTS AWARDED TO DR. CHERQUI FOR HER STEM CELL WORK HAVE BEEN LEVERAGED BY MULTI-MILLION-DOLLAR GRANTS FROM OTHER FUNDING AGENCIES. IF THIS TREATMENT WORKS, IT COULD STOP THE PROGRESSION OF CYSTINOSIS OR BE THE CURE FOR CYSTINOSIS.Since cystinosis is a systemic disease and affects every cell, CRF has targeted multiple areas of research including kidney disease, muscle wasting, neurological issues, corneal cystinosis, and stem cell and gene therapy, all with the goal of finding better treatments and a cure for cystinosis. CRF RESEARCH LEADS TO NEW DISCOVERIES IN OTHER MORE PREVALENT DISEASESAlthough CRF is focused on cystinosis research, discoveries made by CRF-funded researchers are being applied to other diseases including Friedreichs ataxia, Danon disease, Alzheimers disease, and other genetic and systemic diseases like cystinosis. As a result, breakthroughs initially aimed at helping the cystinosis community are now offering potential benefits to patients affected by other debilitating diseases. By advancing understanding of the underlying mechanisms of cystinosis, we have identified potential treatments that are relevant to other disease communities, creating pathways to cures for their communities. We are changing lives and giving hope to people far beyond the cystinosis community.CRF FAMILIES AND PARTNERSThe Cystinosis Research Foundation has witnessed tremendous growth over the years as cystinosis families have joined our fundraising efforts. Cystinosis families from all over the world have embraced the cystinosis cause and have enthusiastically raised funds to support cystinosis research through CRF. Their commitment to research has not only raised significant funds for research, but also created a strong and united global community of action. We have found strength in numbers and our joint effort gives us a renewed sense of community and purpose.DAY OF HOPE CONFERENCEEach year the Cystinosis Research Foundation hosts the Day of Hope Family Conference. In 2025, 59 families from around the world gathered to share their stories, hopes, and dreams and to build life-long friendships. Leading CRF-funded researchers attended the conference and updated the cystinosis community on their research progress including progress on gene and stem cell therapies, novel eye research, and neurological research. The conference educates cystinosis families about current and ongoing research and offers them hope that brighter days are ahead for cystinosis patients. CURE CYSTINOSIS INTERNATIONAL REGISTRYLaunched in April 2012, the Cure Cystinosis International Registry (CCIR) is an important program in the cystinosis community. The registry tracks patients natural history data, collects data about current treatments, identifies known and unknown medical complications, and collects information about quality-of-life issues. The CCIR is a central hub of information for the global community. The deidentified patient data from the registry can be shared with cystinosis clinicians, researchers, and scientists who are pursuing research focused on better treatments and a cure for cystinosis. Today, more than 171 cystinosis patients have registered with CCIR. CRF INTERNATIONAL RESEARCH SYMPOSIUMCRFs International Research Symposium is held every two years and is a highlight for cystinosis researchers. Attendees are CRF-funded researchers and scientists from around the world. Approximately 60 cystinosis experts from leading international universities and research institutions are invited to give presentations about their work. Attendees share their research progress and are encouraged to form collaborations to accelerate the research process. The symposium has solidified the global research community and created a synergistic research community working in partnership with CRF.

    $3,072,586 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 89¢ went to programs, 6¢ to management and 5¢ to fundraising.

  • Programs $3,072,586
  • Management $185,264
  • Fundraising $171,371

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score75 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves26.3 mo; 15.5 mo in cash18.2 / 25
Financial balance (median margin)+2.7%10.8 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+3.8% / yr9.4 / 15
Track record23 years9.2 / 10
Debt load25.0% of assets7 / 10
Total74.7 → 75
Spending on programs
Not scored; America's Best needs 65%+
89%Meets

Compared with Newport Beach peers

MeasureThis organizationPeer median
Operating reserves26.3 mo1.7 mo
Typical margin+2.7%−13.5%
Spending growth+3.8% / yr−4.5% / yr
Debt load25.0%96.2%

Peers: the 4 Newport Beach medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$3,177,424Fiscal year 20252022: $3,589,44720222023: $3,244,97520232024: $3,187,30520242025: $3,177,4242025
Expenses$3,438,007Fiscal year 20252022: $3,072,71320222023: $2,871,72020232024: $4,157,21220242025: $3,438,0072025
Total assets$10,029,960Fiscal year 20252022: $10,168,65720222023: $10,305,66620232024: $10,415,38420242025: $10,029,9602025
Total liabilities$2,507,429Fiscal year 20252022: $1,942,49820222023: $1,643,15020232024: $2,669,29320242025: $2,507,4292025
Fiscal year ending June 2025
Revenue$3,177,424
Expenses$3,438,007
Net income−$260,583
Net assets$7,522,531

Notable sources of revenue

Percent of total revenue
Contributions$2,445,467
Program services$0
Investment income$731,957
Other (net)$0

Assets / debt

Total assets$10,029,960
Total liabilities$2,507,429
Net assets$7,522,531

Compensation

Not in our extract for this year.

Fiscal year ending June 2024
Revenue$3,187,305
Expenses$4,157,212
Net income−$969,907
Net assets$7,746,091

Notable sources of revenue

Percent of total revenue
Contributions$2,739,787
Program services$0
Investment income$447,518
Other (net)$0

Assets / debt

Total assets$10,415,384
Total liabilities$2,669,293
Net assets$7,746,091

Compensation

Not in our extract for this year.

Fiscal year ending June 2023
Revenue$3,244,975
Expenses$2,871,720
Net income$373,255
Net assets$8,662,516

Notable sources of revenue

Percent of total revenue
Contributions$2,894,123
Program services$0
Investment income$241,777
Other (net)$109,075

Assets / debt

Total assets$10,305,666
Total liabilities$1,643,150
Net assets$8,662,516

Compensation

Officers and key employees$0
Share of expenses0.0%
Fiscal year ending June 2022
Revenue$3,589,447
Expenses$3,072,713
Net income$516,734
Net assets$8,226,159

Notable sources of revenue

Percent of total revenue
Contributions$2,921,004
Program services$0
Investment income$217,021
Other (net)$451,422

Assets / debt

Total assets$10,168,657
Total liabilities$1,942,498
Net assets$8,226,159

Compensation

Officers and key employees$0
Share of expenses0.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?